A London-listed biotech company Hemogenyx Pharmaceuticals has signed a binding agreement with Cellin Technologies, an Estonian cell-therapy company based in Tehnopol Science and Business Park, to manufacture and roll out its CAR-T therapy, HG-CT-1, for patients with relapsed or refractory acute myeloid leukemia, a form of blood cancer that has either returned or never responded to earlier […]